Clinical Application of Five DPP4 Inhibitors Based on Hospital-Based Health Technology Assessment
Objective Five dipeptidyl peptidase 4 inhibitors(DPP-4i)(sitagliptin,vildagliptin,saxagliptin,linagliptin and alogliptin)were evaluated through hospital-based health technology assessment(HB-HTA)in order to provide basis for drug selection and clinical rational use in medical institutions.Methods Through HB-HTA,five types of DPP-4i were evaluated in terms of safety,efficacy,economy,innovation,suitability and accessibility based on a percentage scoring system,referring to drug instructions,clinical guidelines,and literature.Results The scores of siagliptin,vigagliptin,sagagliptin,ligagliptin and agragliptin were 85.0,75.0,77.0,80.0 and 78.5,respectively.The main differences in ratings were in terms of safety,economy,suitability and accessibility.Sigliptin had the highest overall score.Conclusion The HB-HTA evaluation of DPP-4i is relatively reasonable,providing a basis for hospital drug selection and safe and reasonable use.
hospital-based health technology assessmentdrug selectiondipeptidyl peptidase 4 inhibitorssafetyeffectiveness
万方数据
维普
